The label for Metformin Hydrochloride was updated on 2026-05-07 to include a new boxed warning. This warning highlights the risk of lactic acidosis, a serious adverse event observed in postmarketing cases, which has been associated with death, hypothermia, hypotension, and resistant bradyarrhythmias.
What this means
The inclusion of a boxed warning on the Metformin Hydrochloride label serves as a critical update for healthcare providers. It emphasizes the severe risks associated with metformin-associated lactic acidosis, which has been reported in postmarketing cases. Clinicians must be acutely aware of the potential for this life-threatening condition, especially given its often subtle onset. The warning specifically highlights that lactic acidosis can manifest with dire consequences, including death, hypothermia, hypotension, and resistant bradyarrhythmias. This necessitates careful patient monitoring and a high index of suspicion, particularly when patients present with non-specific symptoms that could mask the underlying acidosis. Understanding these specific manifestations is crucial for timely diagnosis and intervention to mitigate the serious outcomes described in the warning.
Source
The information regarding this significant label revision for Metformin Hydrochloride was officially released by the FDA. The update, which became effective on 2026-05-07, is publicly accessible through the DailyMed database hosted on dailymed.nlm.nih.gov. This source provides the authoritative details of the new boxed warning, explicitly outlining the risks of lactic acidosis, its subtle onset, and the severe postmarketing outcomes observed, such as death, hypothermia, hypotension, and resistant bradyarrhythmias, ensuring transparency and critical safety information for all stakeholders.